

CITATION REPORT

List of articles citing

Capecitabine: a review

DOI: 10.1016/j.clinthera.2005.01.005
Clinical Therapeutics, 2005, 27, 23-44.

Source: <https://exaly.com/paper-pdf/39360320/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
530	Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. 2005 , 19, 1915-6		4
529	A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors. 2005 , 19, 1922-4		1
528	The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. 2005 , 19, 1912-5		23
527	Inhibition of neutrophil function by the Kaposi's sarcoma-associated herpesvirus vOX2 protein. 2005 , 19, 1907-10		32
526	K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. 2005 , 19, 1916-9		28
525	HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxynucleotide. 2005 , 19, 1924-5		8
524	Inhibition of HIV-1 group M and O isolates by fusion inhibitors. 2005 , 19, 1919-22		15
523	Effect of GB virus C viremia on HIV acquisition and HIV set-point. 2005 , 19, 1910-2		9
522	The Importance of Balancing Toxicity and Efficacy in Chemotherapy. 2005 , 4, 127-136		1
521	Acute coronary syndrome induced by oral capecitabine. 2006 , 22, 251-3		27
520	Radiation modifiers: treatment overview and future investigations. 2006 , 20, 119-39		8
519	Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. 2006 , 7, 321-5		4
518	Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. 2006 , 49, 7002-12		38
517	Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment. 2006 , 55, S119-20		19
516	A rare variant of porokeratosis: porokeratosis ptychotropica. 2006 , 55, S120-2		13
515	[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine]. 2006 , 97, 536-8		4
514	Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats. 2006 , 31, 265-85		11

513	Hepatocellular carcinoma presenting as multifocal haemorrhagic encephalitis. 2006 , 18, 574-6	
512	Bilateral avascular necrosis of the hips after chemoradiotherapy for cervical cancer. 2006 , 18, 576-7	5
511	Pharmacogenetics of capecitabine in advanced breast cancer patients. 2006 , 12, 5496-502	91
510	5'-O-tritylated nucleoside derivatives: inhibition of thymidine phosphorylase and angiogenesis. 2006 , 70, 501-9	28
509	Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. 2006 , 66, 8558-64	82
508	The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. 2007 , 96, 61-6	14
507	Meta analysis of advanced cancer survival data using lognormal parametric fitting: a statistical method to identify effective treatment protocols. 2007 , 13, 1533-44	9
506	A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. 2007 , 72, 33-8	16
505	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. 2007 , 18, 1810-6	28
504	Anthracycline-formaldehyde conjugates and their targeted prodrugs. 2008 , 283, 141-70	10
503	Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. 2007 , 12, 375-89	27
502	Capecitabine-induced headache responding to diltiazem. 2007 , 53, 306-8	1
501	Pharmacogenomics in Colorectal Cancer. 2007 , 5, 117-123	
500	Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. 2007 , 25, 2212-7	467
499	DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. 2007 , 31, 413	1
498	Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. 2007 , 30, 649-55	13
497	Medullary thyroid cancer treated by capecitabine. 2007 , 18, 831-4	7
496	Oral capecitabine (Xeloda) in cancer treatment. 2007 , 32, 18-21	

495	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. 2007 , 43, 14-34	198
494	Should DPD analysis be required prior to prescribing fluoropyrimidines?. 2007 , 43, 1011-6	94
493	Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. 2007 , 39, 565-75	26
492	Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues. 2007 , 61, 596-600	6
491	Prodrugs of Amines. 2007 , 801-831	1
490	First-line treatment strategies for elderly patients with metastatic colorectal cancer. 2007 , 24, 223-38	12
489	Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?. 2007 , 32, 519-21	11
488	Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. 2007 , 17, 739-63	38
487	Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. 2007 , 74, 1555-67	60
486	Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer. 2007 , 78, 543-4	10
485	[Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer]. 2007 , 58, 619-22	1
484	Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. 2007 , 60, 321-8	46
483	Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. 2007 , 25, 237-45	5
482	Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. 2007 , 105, 133-8	12
481	The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. 2007 , 26, 85-110	183
480	Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. 2008 , 97, 1109-34	117
479	Small-molecule based delivery systems for alkylating antineoplastic compounds. 2008 , 3, 536-42	19
478	Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. 2008 , 870, 117-20	12

477	Stevens-Johnson syndrome after treatment with capecitabine. 2008 , 20, 202-3	12
476	Prodrugs: design and clinical applications. 2008 , 7, 255-70	991
475	Granulomatous septal panniculitis associated with capecitabine (Xeloda). 2008 , 22, 121-2	3
474	Pyogenic granuloma-like lesions caused by capecitabine therapy. 2008 , 33, 652-3	8
473	Acquired perforating dermatosis appearing as elastosis perforans serpiginosa and perforating folliculitis. 2008 , 33, 653-4	6
472	Candidate mechanisms for capecitabine-related hand-foot syndrome. 2008 , 66, 88-95	69
471	Nail and periungual toxicity following capecitabine therapy. 2008 , 66, 325-6	11
470	The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy. 2008 , 76, 188-97	37
469	Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. 2008 , 36, 413-23	43
468	Dose calculation of anticancer drugs. 2008 , 4, 1307-19	30
467	Capecitabine induced vasospastic angina. 2008 , 130, e34-6	16
466	Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. 2008 , 59, S4-6	34
465	Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases. 2008 , 5, 539-542	6
464	S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. 2009 , 39, 49-53	18
463	Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?. 2008 , 14, 8-13	56
462	Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. 2008 , 54, 352-6	13
461	Onycholysis associated with capecitabine in patients with breast cancer. 2008 , 12, 93-5	5
460	A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. 2008 , 9, 336-43	56

459	Capecitabine-associated cerebellar ataxia. 2008 , 65, 2032-5	4
458	Appendiceal carcinoma: a diagnostic and therapeutic challenge. 2008 , 120, 95-100	7
457	Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. 2008 , 23, 647-53	48
456	Mesojejunoileac liposarcoma with intrahepatic metastasis in a dog. 2008 , 70, 637-40	6
455	Chemotherapy and targeted agents for elderly women with advanced breast cancer. 2008 , 3, 187-201	16
454	Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine. 2008 , 30, 172-3	6
453	Paralytic Ileus Associated with Capecitabine. 2008 , 94, 742-745	1
452	Factors that affect cancer patient compliance to oral anti-neoplastic therapy. 2008 , 21, 323-329	13
451	Capecitabine: treatment options in metastatic breast cancer. 2009 , 4, 367-376	
450	Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. 2009 , 15, 6649-57	47
449	Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer. 2009 , 12, 238-45	5
448	Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. 2009 , 15, 2920-6	694
447	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. 2009 , 100, 1720-4	27
446	Actual and potential agents and biomarkers in the treatment of cancer. 2009 , 9, 500-16	7
445	Human nucleoside transporters: biomarkers for response to nucleoside drugs. 2009 , 28, 450-63	28
444	The dual role of thymidine phosphorylase in cancer development and chemotherapy. 2009 , 29, 903-53	143
443	Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. 2009 , 17, 1081-8	11
442	Systemic therapy of advanced urothelial cancer. 2009 , 10, 256-66	20

441	Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. 2009 , 65, 1057-9	6
440	(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. 2009 , 36, 1425-33	27
439	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. 2009 , 64, 1021-7	8
438	Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells. 2009 , 73, 853-60	11
437	Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. 2009 , 69, 1951-7	421
436	Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine. 2009 , 52, 7678-88	23
435	A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. 2009 , 45, 1935-49	77
434	Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. 2009 , 33, 373-9	29
433	Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. 2009 , 109, 2880-93	385
432	Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. 2009 , 53, 2231-47	885
431	Proteolysis: a biological process adapted in drug delivery, therapy, and imaging. 2009 , 20, 1683-95	107
430	Regioselective metalation of 6-methylpurines: synthesis of fluoromethyl purines and related nucleosides for suicide gene therapy of cancer. 2009 , 28, 642-56	3
429	Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane. 2009 , 84, 533-545	66
428	Advances in the treatment of metastatic colorectal cancer. 2009 , 16, 412-20	34
427	Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. 2009 , 20, 217-29	35
426	Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report. 2009 , 10, 722-6	11
425	The role of capecitabine in the management of tumors of the digestive system. 2009 , 4, 1-11	5
424	Capecitabine (Xeloda): An Oral Chemotherapy Agent. 2010 , 57-71	1

423	Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. 2010 , 65, 755-63	20
422	Increased anticoagulant activity of warfarin used in combination with doxifluridine. 2010 , 66, 969-72	8
421	Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. 2010 , 1, 495-502	18
420	Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. 2010 , 124, 177-86	11
419	Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare. 2010 , 80, 1528-36	41
418	[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. 2010 , 34, 218-23	2
417	An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. 2010 , 45, 670-7	21
416	Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. 2010 , 102, 1687-91	38
415	Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. 2010 , 103, 1680-91	38
414	. 2010 ,	29
413	Capecitabine-induced cardiotoxicity: case report and review of the literature. 2010 , 17, 59-63	26
412	Capecitabine-induced pancreatitis. 2010 , 16, 133-4	15
411	Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. 2010 , 70, 6902-12	44
410	Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. 2010 , 28, 4554-61	43
409	Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs. 2010 , 83-150	
408	5-fluorouracil for actinic keratoses. 2010 , 5, 131-139	9
407	An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?. 2010 , 42, 326-8	12
406	Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. 2010 , 10, 505-12	41

405	A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. 2010 , 3, 373-9	16
404	Mismatch repair deficient colorectal cancer in the era of personalized treatment. 2010 , 7, 197-208	165
403	Topics in clinical pharmacology: renal, gastrointestinal, and pain management. 2010 , 56, 187-250	1
402	Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo. 2010 , 94, 1632-8.e1	13
401	Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. 2010 , 6, 419-28	80
400	Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. 2011 , 51, 1674-84	18
399	Nanostructured self-assembly materials from neat and aqueous solutions of C18 lipid pro-drug analogues of Capecitabine chemotherapy agent. Focus on nanoparticulate cubosomes of the oleyl analogue. 2011 , 7, 5764	17
398	Optimal management of metastatic colorectal cancer: current status. 2011 , 71, 869-84	8
397	Challenges of ensuring adherence to oral therapy in patients with solid malignancies. 2011 , 8, 254-262	3
396	Capecitabine-phenytoin interaction is dose dependent with an unexpected time course. 2011 , 22, 1027-9	4
395	Capecitabine in the management of colorectal cancer. 2011 , 79	7
394	Increased Mean Corpuscular Volume of Erythrocytes during Capecitabine Treatment: A Simple Surrogate Marker for Clinical Response. 2011 , 97, 711-716	6
393	Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. 2011 , 12, 918-31	9
392	Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications. 2011 , 36, 411-22	16
391	The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes. 2011 , 82, 441-52	27
390	Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. 2011 , 28, 1136-9	3
389	Molecular-biological problems of drug design and mechanism of drug action. 2011 , 44, 651-653	4
388	Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells. 2011 , 38, 3679-88	11

387	Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. 2011 , 19, 1009-18	85
386	Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. 2011 , 68, 1413-9	34
385	Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?. 2011 , 5, 129-140	9
384	Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. 2011 , 46, 2867-79	18
383	The role and impact of SNPs in pharmacogenomics and personalized medicine. 2011 , 12, 460-86	40
382	Häufige Haut-Nebenwirkungen von neuen onkologischen Medikamenten. 2011 , 37, 451-457	1
381	Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacy. 2011 , 51, 117-9	4
380	A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. 2011 , 17, 2006-13	58
379	Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment. 2011 , 147, 998-9	13
378	Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes. 2011 , 57, 71-6	10
377	Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. 2011 , 12, 1321-36	146
376	Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. 2011 , 301, G347-55	24
375	Toward a new age of cellular pharmacokinetics in drug discovery. 2011 , 43, 335-45	38
374	Clinical Response of Metastatic Breast Cancer to Multi-targeted Therapeutic Approach: A Single Case Report. 2011 , 3, 1454-66	1
373	A Case Report: hand-foot Syndrome Accompanied By Severe Oral Lesions During Capecitabine Therapy For Metastatic Colon Carcinoma. 2011 ,	0
372	Superparamagnetic Nanoparticles and RNAi-Mediated Gene Silencing: Evolving Class of Cancer Diagnostics and Therapeutics. 2012 , 2012, 1-15	7
371	Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. 2012 , 107, 1268-76	18
370	Involvement of target gene polymorphisms in 5-Fluorouracil toxicity: a case report. 2012 , 89, 99-102	3

369	Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. 2012 , 58, 371-80	2
368	Chemotherapy Combined with Radionuclide Therapy. 2012 , 901-908	
367	Irinotecan-induced dysarthria. 2012 , 5, 47-51	11
366	Rapid continuous synthesis of 5'-deoxyribonucleosides in flow via Brønsted acid catalyzed glycosylation. 2012 , 14, 3348-51	35
365	Unilateral hand-foot syndrome: does it take sides? Case report and literature review. 2012 , 11, 82-4	8
364	Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. 2012 , 12, 172	36
363	Polymer-Based Nanoparticulate Systems as Versatile Agents in the Prognosis and Therapy of Cancer. 2012 , 82, 37-58	
362	Identification of novel germline polymorphisms governing capecitabine sensitivity. 2012 , 118, 4063-73	23
361	A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer. 2012 , 27, 727-36	16
360	Resolving actinic keratoses: an expected side-effect of capecitabine therapy. 2012 , 37, 68-9	5
359	Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase. 2012 , 8, 247-58	19
358	Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. 2013 , 14, 480	19
357	Side Effects of Medical Cancer Therapy. 2013 ,	2
356	DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. 2013 , 14, 1255-72	93
355	Potential of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma. 2013 , 112, 237-44	76
354	Magnetic nanoparticle-based cancer nanodiagnostics. 2013 , 22, 058702	11
353	Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. 2013 , 108, 2505-15	109
352	Pharmaceutical nanotechnology for oral delivery of anticancer drugs. 2013 , 65, 880-90	252

351	Slow dissolution behaviour of amorphous capecitabine. 2013 , 441, 213-7	20
350	Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. 2013 , 71, 287-92	3
349	Synthesis of 3'-azido-2',3'-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity. 2013 , 67, 188-95	16
348	Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. 2013 , 107, 184-8	39
347	Brain metastases from HER2-positive breast cancer. 2013 , 14, e3	2
346	Cancer Drugs. 2013 , 287-336	
345	Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?. 2013 , 13, 167-72	18
344	Designing polymeric microparticles for biomedical and industrial applications. 2013 , 49, 2005-2021	115
343	Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma. 2013 , 72, 777-88	7
342	Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. 2013 , 3,	32
341	Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. 2013 , 13, e11721	23
340	Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. 2013 , 59, 232-8	22
339	Metal-organic frameworks as potential drug delivery systems. 2013 , 10, 89-101	260
338	Purtscher-like retinopathy in association with metastatic pancreatic adenocarcinoma and capecitabine therapy. 2013 , 7, 196-7	2
337	Use of neostigmine in capecitabine-induced paralytic ileus. 2013 , 99, e225-e228	0
336	Acute presentation of vasospastic angina induced by oral capecitabine: a case report. 2014 , 8, 18	9
335	Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. 2014 , 8, 246	33
334	Capecitabine-induced Toxicity: An Outcome Study into Drug Safety. 2014 , 03,	4

333	Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer. 2014 , 51, 186-91	21
332	Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?. 2014 , 20, 6092-101	23
331	Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. 2014 , 2014,	11
330	Chloroquine and hydroxychloroquine for cancer therapy. 2014 , 1, e29911	120
329	Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. 2014 , 74, 751-6	14
328	5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells. 2014 , 7, 541-547	26
327	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. 2014 , 148, 197-209	6
326	Crystal structure and tautomerism of capecitabine. 2014 , 103, 587-93	11
325	Stability study of the gastric floating dosage form of capecitabine. 2014 , 115, 2495-2499	3
324	Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. 2014 , 28, 229-36	12
323	Evaluation of Montmorillonite/Poly (L-Lactide) microcomposite spheres as ambidextrous reservoirs for controlled release of Capecitabine (Xeloda) and assessment of cell cytotoxic and oxidative stress markers. 2014 , 90, 193-201	14
322	Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). 2014 , 114, 2432-506	2974
321	Interaction of 5-fluoro-5'-deoxyuridine with human serum albumin under physiological and non-physiological condition: a biophysical investigation. 2014 , 123, 469-77	76
320	Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. 2014 , 181, 193-207	10
319	Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy. 2014 , 21, 673-81	10
318	Personalizing medicine in geriatric oncology. 2014 , 32, 2581-6	32
317	Design and synthesis of pyrimidine molecules endowed with thiazolidin-4-one as new anticancer agents. 2014 , 83, 630-45	31
316	Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. 2014 , 14, 13-9	33

315	Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. 2014 , 103, 478-84	5
314	KIN enhances stem cell-like properties to promote chemoresistance in colorectal carcinoma. 2014 , 448, 63-9	4
313	FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. 2014 , 20, 10316-30	54
312	Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma. 2014 , 48, 189-96	5
311	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. 2015 , 6, 17	10
310	Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: clinical and occupational implications. 2015 , 46, 1893-900	14
309	Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. 2015 , 101, 418-23	7
308	MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. 2015 , 48, 503-10	53
307	Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. 2015 , 10, e0115686	160
306	Combined Effect of Vorinostat and Grape Seed Proanthocyanidins on Modulation of Thymidine Phosphorylase in Non-Small Cell Lung Cancer. 2015 , 14, 953	1
305	Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. 2015 , 20, 39-70	56
304	Nasal septum perforation in the patients with advanced breast cancer due to the treatment of lapatinib+capecitabine. 2015 ,	
303	Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatment. 2015 , 49, 181-4	1
302	A Two-Photon Ratiometric Fluorescent Probe for Imaging Carboxylesterase 2 in Living Cells and Tissues. 2015 , 7, 28474-81	82
301	Organic carbamates in drug design and medicinal chemistry. 2015 , 58, 2895-940	346
300	Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). 2015 , 36, 3361-9	4
299	Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. 2015 , 4, 383-91	22
298	Lipid prodrug nanocarriers in cancer therapy. 2015 , 208, 25-41	80

297	Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. 2015 , 34, 2672-80	35
296	Case series: five individuals diagnosed with breast and gastrointestinal cancers: are they "related"?. 2015 , 42, e1-12	1
295	Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. 2015 , 989, 71-9	20
294	Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. 2015 , 12, 2417-24	36
293	Genotoxic Impurities in Pharmaceutical Manufacturing: Sources, Regulations, and Mitigation. 2015 , 115, 8182-229	97
292	Strategies for formulating and delivering poorly water-soluble drugs. 2015 , 30, 342-351	84
291	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. 2015 , 47, 518-22	46
290	Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. 2015 , 75, 1183-9	9
289	Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. 2015 , 23, 1311-9	14
288	The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. 2015 , 6, 1460-9	75
287	Pharmacogenomics of fluorouracil -based chemotherapy toxicity. 2015 , 11, 811-21	32
286	Synthesis of the antitumoral nucleoside capecitabine through a chemo-enzymatic approach. 2015 , 56, 5909-5913	7
285	Evaluation of the aquatic toxic effect varied during the degradation of capecitabine under the environmental abiotic and biotic processes. 2015 , 5, 76772-76778	10
284	A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. 2015 , 45, 79-87	49
283	Low-dose Metronomic Capecitabine (Xeloda) for Treatment of Metastatic Gastrointestinal Cancer: A Clinical Study. 2016 , 4,	1
282	Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. 2016 , 7, 310	11
281	Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. 2016 , 7, 414	95
280	Preparation of a ZnO nanoparticles/multiwalled carbon nanotubes/carbon paste electrode as a sensitive tool for capecitabine determination in real samples. 2016 , 6, 33851-33856	12

279	Drug-induced hepatotoxicity in cancer patients - implication for treatment. 2016 , 15, 1219-38	33
278	Therapeutic drug monitoring of 5-fluorouracil. 2016 , 78, 447-64	110
277	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates. 2016 , 24, 2330-41	8
276	Capecitabine for treating head and neck cancer. 2016 , 25, 851-9	6
275	Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-Fluorouracil and Temozolomide. 2016 , 92, 276-86	18
274	A highly selective near-infrared fluorescent probe for carboxylesterase 2 and its bioimaging applications in living cells and animals. 2016 , 83, 193-9	79
273	Antineoplastic Agents. 2016 , 495-547	6
272	Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. 2016 , 50, 247-263	29
271	Magnetic Nanostructures for MRI-Based Cancer Detection. 2016 , 327-359	
270	Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. 2016 , 14, 507-534	1
269	Capecitabine-related liver lesions: sinusoidal dilatation mimicking liver metastasis. 2016 , 4, 545-8	2
268	Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. 2016 , 116, 14379-14455	167
267	Prodrug Approaches to Drug Delivery. 2016 , 227-271	6
266	Comparative analysis of the interaction of capecitabine and gefitinib with human serum albumin using (19)F nuclear magnetic resonance-based approach. 2016 , 129, 15-20	11
265	Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. 2016 , 5, 1675	1
264	MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer. 2016 , 40, 62-76	63
263	Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer. 2016 , 124, 992-1003	18
262	CE: A Review of Common Oral Treatments for Breast Cancer: Improving Patient Safety in Nononcology Settings. 2016 , 116, 28-36	

261	Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. 2016 , 22, 552-5	9
260	A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma. 2016 , 22, 717-9	2
259	3'-O- and 5'-O-Propargyl Derivatives of 5-Fluoro-2'-Deoxyuridine: Synthesis, Cytotoxic Evaluation and Conformational Analysis. 2016 , 35, 178-94	6
258	Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. 2016 , 81, 36-41	15
257	Trial watch - inhibiting PARP enzymes for anticancer therapy. 2016 , 3, e1053594	18
256	The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. 2017 , 1863, 917-928	1
255	5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. 2017 , 174, 3713-3726	22
254	Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. 2017 , 102, 796-804	18
253	Synergistic antitumor activity of a self-assembling camptothecin and capecitabine hybrid prodrug for improved efficacy. 2017 , 263, 102-111	45
252	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. 2017 , 7, 42499	25
251	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. 2017 , 18, 371-383	29
250	The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. 2017 , 49, 158-196	17
249	Cardio-Oncology. 2017 ,	1
248	The Role of Fluoropyrimidines in Gastrointestinal Tumours: from the Bench to the Bed. 2017 , 48, 135-147	2
247	Synthesis of Antitumor Fluorinated Pyrimidine Nucleosides. 2017 , 49, 69-154	9
246	Breast Cancer Cardio-Oncology. 2017 , 241-252	
245	Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine. 2017 , 31, e304-e306	2
244	[F]fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon Cancer. 2017 , 77, 7120-7130	5

243	Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. 2017 , 170, 548-563.e16	765
242	Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. 2017 , 70, 2536-2551	192
241	MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy. 2017 , 18, 1027-1038	5
240	Prodrugs in medicinal chemistry and enzyme prodrug therapies. 2017 , 118, 65-77	124
239	New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin. 2017 , 62, 62-70	25
238	Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. 2017 , 73, 157-164	10
237	Hiperpigmentaci3 secundaria a capecitabina, 2 patrones diferentes de presentaci3. 2017 , 32, 7-10	0
236	Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from cancer patients. 2017 , 1040, 22-37	26
235	Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System. 2017 , 7, 220	2
234	Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 2017 , 18, 208-211	9
233	The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. 2017 , 9, 495-514	7
232	Neoadjuvant Chemotherapy With Capecitabine Plus Cisplatin in Patients With Locally Advanced Nasopharyngeal Cancer: Case Series Study. 2017 , 3, 455-458	1
231	Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. 2018 , 44, 1572-1582	31
230	Arterial Thrombosis in Patients with Cancer. 2018 , 20, 40	32
229	Theoretical prediction of chloroform, ethanol, water and DMSO effects on electronic characteristics of Capecitabine different conformers as an anticancer chemotherapy drug. 2018 , 264, 115-118	16
228	Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy. 2018 , 20, 1280-1288	3
227	Pro-survival autophagy and cancer cell resistance to therapy. 2018 , 37, 749-766	73
226	Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. 2018 , 101, 458-477	76

225	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 2018 , 144, 403-414	28
224	A multi-throughput multi-organ-on-a-chip system on a plate formatted pneumatic pressure-driven medium circulation platform. 2017 , 18, 115-125	84
223	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. 2018 , 9, 25355-25382	22
222	New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer. 2018 , 36, 609-616	29
221	Capecitabine-Associated Myocardial Infarction. 2018 , 25, e737-e739	0
220	Administration of High-Dose Vitamin C and Irinotecan Ameliorates Colorectal Cancer Induced by Azoxymethane and Dextran Sodium Sulfate in Mice. 2018 , 41, 1797-1803	6
219	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. 2018 , 9,	5
218	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. 2018 , 104, 210-218	5
217	Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells. 2018 , 37, 436-454	1
216	A new, sensitive and versatile assay for quantitative determination of Fluoro-Alanine (AFBA) in human urine by using the reversed-phase ultrahigh performance-tandem mass spectrometry (rp-UHPLC-MS/MS) system. 2018 , 298, 164-170	1
215	Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population. 2018 , 5, 161-167	2
214	Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. 2018 , 9, 1607	47
213	Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients. 2018 , 40, 495-502	4
212	Multinuclear NMR Measurements and DFT Calculations for Capecitabine Tautomeric Form Assignment in a Solution. 2018 , 23,	5
211	Management of leptomeningeal metastasis in breast cancer. 2018 , 172, 151-159	11
210	Physiological concentrations of phytosterols enhance the apoptotic effects of 5-fluorouracil in colon cancer cells. 2018 , 49, 52-60	4
209	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker. 2019 , 29, 2587-2594	5
208	A non-toxic approach for treatment of breast cancer and its metastases: capecitabine enhanced photodynamic therapy in a murine breast tumor model. 2019 , 5,	3

207	Detection of Superoxide Alterations Induced by 5-Fluorouracil on HeLa Cells with a Cell-Based Biosensor. 2019 , 9,	4
206	Continuous-Flow Sequential SchottenBaumann Carbamoylation and Acetate Hydrolysis in the Synthesis of Capecitabine. 2019 , 23, 2516-2520	8
205	prevents apoptosis in colorectal cancer cells via the ANO1 pathway. 2019 , 11, 9057-9066	4
204	LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. 2019 , 19, 234	56
203	QTAIM, NBO, and NMR studies of hydrogen bonds in capecitabine. 2019 , 150, 1267-1274	4
202	Advancement in the development of heterocyclic nucleosides for the treatment of cancer - A review. 2019 , 38, 836-857	21
201	Benzoxaboroles as dynamic covalent receptors for bioconjugation and transport of nucleosides and related drugs: Proof of action in HeLa cells. 2019 , 90, 103059	4
200	Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. 2019 , 22, 112-121	1
199	Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. 2019 , 83, 1127-1135	9
198	Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. 2019 , 36, 394-402	6
197	Capecitabine-induced Subacute Cutaneous Lupus Erythematosus. 2019 , 94, 618-619	1
196	Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. 2019 , 160, 110-120	10
195	Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents. 2019 , 27, 748-759	2
194	Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy. 2019 , 37, 42-53	13
193	A molecular basis for the synergy between 17-allylamino-17-demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEGF and MMP-9 gene expression. 2019 , 684, 30-38	16
192	Capecitabine as a minor groove binder of DNA: molecular docking, molecular dynamics, and multi-spectroscopic studies. 2019 , 37, 1451-1463	12
191	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. 2020 , 20, 136-158	11
190	Conventional chemotherapy. 2020 , 127-153.e11	1

189	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). 2020 , 38, 203-213	45
188	Therapeutic potential of uracil and its derivatives in countering pathogenic and physiological disorders. 2020 , 207, 112801	6
187	Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation. 2020 , 19, 378-383	1
186	Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy. 2020 ,	0
185	Conditions for the Implementation of a Patient Education Program Dedicated to Cancer Patients Treated by Oral Anticancer Therapy. 2020 , 14, 2263-2277	
184	An efficient synthesis of 6-benzyl-2-arylthieno[2,3-d]pyrimidin-4(3H)-ones catalyzed by HCl involving a Friedel-Crafts alkylation reaction. 2020 , 57, 3970-3979	
183	Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs. 2020 , 40, 4655-4661	5
182	Bioelectric Sensors: On the Road for the 4.0 Diagnostics and Biomedtech Revolution. 2020 , 10,	1
181	Dose Intensified Chemoradiation and Intraluminal Brachytherapy Improve Outcomes in Middle Third Carcinoma Esophagus: Experience from a Regional Cancer Center. 2020 , 6, 61-64	
180	Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. 2020 , 105,	9
179	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. 2020 , 5, 193	27
178	Synthesis of Thiol Derivatives of Biological Active Compounds for Nanotechnology Application. 2020 , 25,	5
177	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. 2020 , 11, 600886	11
176	Ortho-(1-phenylvinyl)benzyl glycosides: Ether-type glycosyl donors for the efficient synthesis of both O-glycosides and nucleosides. 2020 , 1, 160-166	5
175	Oral Chemotherapy for Treatment of Lung Cancer. 2020 , 10, 793	8
174	Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. 2020 , 25,	3
173	Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience. 2020 , 12, 1387-1396	5
172	Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations. 2020 , 26, 1429-1440	8

171	Beyond Taxonomic Analysis of Microbiomes: A Functional Approach for Revisiting Microbiome Changes in Colorectal Cancer. 2019 , 10, 3117	3
170	Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform. 2020 , 106, 124-135	51
169	5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine. 2020 , 10, 2711	1
168	Glycosyl ortho-(1-phenylvinyl)benzoates versatile glycosyl donors for highly efficient synthesis of both O-glycosides and nucleosides. 2020 , 11, 405	18
167	Silver nanoparticles-tragacanth gel as a green membrane for effective extraction and determination of capecitabine. 2020 , 43, 2666-2674	4
166	Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine. 2020 , 11, 3327-3333	2
165	Effective Oral Administration of an Antitumorigenic Nanoformulated Titanium Complex. 2021 , 16, 108-112	4
164	Molecularly Imprinted Polymer-Based Smart Prodrug Delivery System for Specific Targeting, Prolonged Retention, and Tumor Microenvironment-Triggered Release. 2021 , 60, 2663-2667	42
163	Molecularly Imprinted Polymer-Based Smart Prodrug Delivery System for Specific Targeting, Prolonged Retention, and Tumor Microenvironment-Triggered Release. 2021 , 133, 2695-2699	3
162	Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study). 2021 , 29, 4257-4267	3
161	Green protocols for active pharmaceutical ingredients (API). 2021 , 21-40	
160	Biomaterials for Anticancer Drugs. 2021 , 133-148	
159	Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops. 2021 , 35, 1881-1884	0
158	Oral drugs in the treatment of metastatic colorectal cancer. 2021 , 13, 17588359211009001	9
157	Inclusion of capecitabine into cucurbiturils: DFT study for supramolecular encapsulation of anticancer drug. 2021 , 152, 209-216	
156	Cancer stem cells in colorectal cancer and the association with chemotherapy resistance. 2021 , 38, 43	6
155	Semisynthetic Derivatives of the Verticillin Class of Natural Products through Acylation of the C11 Hydroxy Group. 2021 , 12, 625-630	3
154	Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. 2021 , 11, 8964	2

153	Design, synthesis, and evaluation of potential carbamate prodrugs of 5?-methylthioadenosine (MTA). 2021 , 30, 1358-1365	
152	Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs. 1-74	1
151	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). 2021 , 40, 138	1
150	QbD Approach For Anti-Cancer Drugs - A Review. 2021 , 17,	
149	Capecitabine-Associated Loss of Fingerprints: A Case Report of a 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia. 2021 , 13, e15519	
148	Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis. 2021 , 162, 103346	3
147	FXYP6 Regulates Chemosensitivity by Mediating the Expression of Na ⁺ /K ⁺ -ATPase 1 and Affecting Cell Autophagy and Apoptosis in Colorectal Cancer. 2021 , 2021, 9986376	1
146	Complex Chromosome-Positive Acute Myelogenous Leukemia Identified 16 Months following the Completion of Capecitabine Chemotherapy for Early-Stage Colon Cancer. 2021 , 14, 918-921	0
145	Capcetabine-Induced Discoid Cutaneous Lupus. 2021 , 112, 859-859	0
144	Therapeutic challenges at the preclinical level for targeted drug development for -associated cholangiocarcinoma. 2021 , 30, 985-1006	1
143	Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer. 2021 , 53, 724-732	1
142	Current cancer therapies and their influence on glucose control. 2021 , 12, 1010-1025	3
141	Development of biodegradable thin films for efficient, specific and controlled delivery of capecitabine. 2021 , 16,	
140	The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota. 2021 , 460, 152858	0
139	Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study. 2021 , 38, 4798-4814	0
138	Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopenia. 2021 , 17, 1440-1446	2
137	Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect. 2021 , 12, 737849	2
136	Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. 2021 , 10,	1

135	Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit from the maintenance chemotherapy using S-1/capecitabine?. 2021 , 122, 105539	0
134	Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity. 2021 , 681-696	
133	Transforming early pharmaceutical assessment of genotoxicity: applying statistical learning to a high throughput, multi end point in vitro micronucleus assay. 2021 , 11, 2535	4
132	Fluorouracil or Capecitabine Overdose. 2021 , 739-749	
131	5-Fluorouracil and Its Prodrug Capecitabine: Occurrence, Fate and Effects in the Environment. 2020 , 331-375	1
130	Folate Antagonists. 2011 , 125-143	1
129	Drug-Induced Liver Injury. 2018 , 844-890.e17	1
128	Treatment options for breast cancer resistant to anthracycline and taxane. 2009 , 84, 533-45	31
127	Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. 2010 , 33, 307-13	4
126	Pharmacogenomics, biomarker network and allele frequencies in colorectal cancer.	1
125	Drug resistant gut bacteria mimic a host mechanism for anticancer drug clearance.	1
124	Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. 2016 , 6, e012798	30
123	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. 2019 , 4,	44
122	Genetic influence of polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin. 2020 , 35,	2
121	Side-effects related to adjuvant CAPOX treatment for colorectal cancer are associated with intermuscular fat area, not with total skeletal muscle or fat, a retrospective observational study.. 2018 , 3,	1
120	A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer. 2016 , 7, 84533-84543	10
119	Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. 2016 , 7, 38359-38366	3
118	Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report.. 2019 , 8, 693-698	2

117	Capecitabine in the management of colorectal cancer. 2011 , 3, 79-89	39
116	Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents. 2019 , 26, 7166-7195	41
115	Athymic nude mice as an experimental model for cancer treatment. 2016 , 65, S441-S453	49
114	A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. 2007 , 13, 2135-7	13
113	Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. 2014 , 20, 9775-827	88
112	Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. 2015 , 47, 687-96	9
111	Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. 2020 , 12, 604-618	6
110	Role of colonoscopy in diagnosis of capecitabine associated ileitis: Two case reports. 2019 , 11, 383-388	4
109	A Blood-brain Barrier Permeable Derivative of 5-Fluorouracil: Preparation, Intracellular Localization, and Mouse Tissue Distribution. 2011 , 32, 873-879	12
108	Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. 2014 , 15, 9225-32	12
107	Capecitabine induced fingerprint loss: Case report and review of the literature. 2021 , 10781552211045009	0
106	Capcetabine-Induced Discoid Cutaneous Lupus. 2020 , 112, 859-859	
105	Systemic Chemotherapy of Non-Melanoma Skin Cancer. 2010 , 83-90	
104	Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment. 2013 , 139-161	
103	Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation. 2014 , 287-323	
102	Benign dermoscopic parallel ridge pattern in plantar hyperpigmentation due to capecitabine. 2015 , 5, 79-81	7
101	Cardiovascular Emergencies. 2016 , 179-190	
100	Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment. 2018 , 105-119	1

99	Evaluation of Correlation Between Serum Level of Dihydropyrimidine Dehydrogenase Enzyme and Capecitabine Induced Adverse Reaction. 2018 , 4,	
98	Phenytoin Toxicity During Neoadjuvant Concurrent Capecitabine and Radiation Therapy for Rectal Adenocarcinoma: Case Report of a Drug Interaction. 2018 , 10, e3625	
97	Hepatocellular Carcinoma. 2019 , 207-234	
96	Structural, functional and docking analysis against Schistosoma mansoni dihydroorotate dehydrogenase for potential chemotherapeutic drugs. 8, 651	2
95	Compendium of Mechanistic Insights of Distinct Conventional Anticancer Therapies and Their Grievous Toxicities. 2020 , 111-136	
94	History of Paclitaxel and Oral Paclitaxel [Clinical Data and Future. 2020 , 41, 260-263	
93	Experimental and Theoretical Investigations of the Chemotherapeutic Drug Capecitabine. 2022 , 1250, 131577	0
92	Spectroscopic Characteristics of Xeloda Chemodrug.. 2021 , 12, e51	0
91	Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. 2009 , 3, 134-40	8
90	Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases. 2012 , 5, 103-5	
89	Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. 2012 , 25, 106-118	106
88	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting. 2017 , 10, S8-S41	2
87	Assessment of Magnetic Dextran-Spermine Nanoparticles for Capecitabine Delivery to Cancerous Cells. 2017 , 16, 1320-1334	11
86	The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis. 2021 , 12, 771839	0
85	An overview and bibliometric analysis on the colorectal cancer therapy by magnetic functionalized nanoparticles for the responsive and targeted drug delivery. 2021 , 19, 399	4
84	Capecitabine-associated enterocolitis: Narrative literature review of a rare adverse event and a case presentation.. 2022 , 1-9	2
83	Capecitabine and Warfarin Interaction: A Case Report With Review of Literature and Management Options.. 2021 , 8, 707361	1
82	Advances in Chemoradiotherapy for Treatment of Colon Cancer. 2022 , 217-239	

81	Prodrug-based drug delivery approaches in cancer combination therapy. 2022 , 239-271	
80	Multifunctional role of thymidine phosphorylase in cancer.. 2022 ,	1
79	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. 2022 ,	1
78	Exposure to Antineoplastic Drugs in Occupational Settings: A Systematic Review of Biological Monitoring Data.. 2022 , 19,	4
77	Fusobacterium nucleatum and cancer.. 2022 ,	3
76	The Role of Ferroptosis in the Treatment and Drug Resistance of Hepatocellular Carcinoma.. 2022 , 10, 845232	0
75	Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.. 2022 , 166, 185-201	2
74	Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.. 2022 ,	0
73	Topical henna and curcumin (Alpha β) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.. 2022 , 1	1
72	A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.. 2022 ,	
71	Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. 2022 , 27,	4
70	Image_1.TIF. 2018 ,	
69	Image_2.TIF. 2018 ,	
68	Image_3.TIF. 2018 ,	
67	Image_4.TIF. 2018 ,	
66	Image_5.TIF. 2018 ,	
65	Table_1.XLS. 2018 ,	
64	Data_Sheet_1.ZIP. 2020 ,	

63 Data_Sheet_2.ZIP. **2020**,

62 Data_Sheet_3.ZIP. **2020**,

61 Data_Sheet_4.ZIP. **2020**,

60 Data_Sheet_5.ZIP. **2020**,

59 Data_Sheet_6.zip. **2020**,

58 Table_1.xlsx. **2020**,

57 Table_10.xlsx. **2020**,

56 Table_11.xlsx. **2020**,

55 Table_12.xlsx. **2020**,

54 Table_2.xlsx. **2020**,

53 Table_3.xlsx. **2020**,

52 Table_4.xlsx. **2020**,

51 Table_5.xlsx. **2020**,

50 Table_6.xlsx. **2020**,

49 Table_7.xlsx. **2020**,

48 Table_8.xlsx. **2020**,

47 Table_9.xlsx. **2020**,

46 Capecitabine-induced severe diabetes and hypokalemia: a case report.. **2022**, 16, 163

○

- 45 Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. **2022**, 14, 2470 0
- 44 Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).. **2022**, 23, 420 0
- 43 Pyrimidine-based anticancer drugs. **2022**, 107-142
- 42 SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth. 1
- 41 Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29). **2022**, 78, 103850 0
- 40 PNA-Modified Liposomes Improve the Delivery Efficacy of CAPIRI for the Synergistic Treatment of Colorectal Cancer. 13, 0
- 39 The role of gut microbiota in the development of colorectal cancer: a review. 2
- 38 Subacute cutaneous lupus erythematosus induced by Capecitabine: confocal microscopy and dermoscopy findings. 0
- 37 Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation with Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a single arm study. **2022**,
- 36 Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment. **2022**, 176, 106259 0
- 35 Synthesis, ^{99m}Tc-labeling, in-vivo study and in-silico investigation of 6-amino-5-[(bis-(2-hydroxy-ethyl)-amino)methyl]2-methyl pyrimidin-4-ol as a potential probe for tumor targeting.
- 34 Combination Therapy Comprising Paclitaxel and 5-Fluorouracil by Using Folic Acid Functionalized Bovine Milk Exosomes Improves the Therapeutic Efficacy against Breast Cancer. **2022**, 12, 1143 3
- 33 Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. 0
- 32 Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. **2022**, 27, 5436 6
- 31 Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer. **2022**, 222, 562-572 2
- 30 Re-thinking the possible interaction between proton pump inhibitors and capecitabine. 0
- 29 Capecitabine: A Permanent Mission in Head and Neck Cancers War Council. **2022**, 11, 5582 0
- 28 Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy. 2

27	Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism. 2022 , 7, 1605-1620	2
26	Folic acid conjugated capecitabine capped green synthesized fluorescent carbon dots as a targeted nano-delivery system for colorectal cancer. 2022 , 33, 104590	0
25	Overview of Ovarian Cancer Chemotherapy. 2022 , 129-169	0
24	Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. 2022 , 125-200	0
23	Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. 2022 , 14, 2119	1
22	Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil.	0
21	Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. 2022 , 100917	1
20	Influence of Oxidative Stress on Drug-DNA Binding: Microcalorimetric and Mechanistic Insights with Anticancer Drugs. 2022 , 120769	0
19	DIFFUSE REFLECTANCE FOURIER TRANSFORM INFRARED SPECTROSCOPIC QUANTIFICATION OF TWO NOVEL DRUGS IN PHARMACEUTICALS: A NEW CASE STUDY FOR CHEMOMETRICS ASSISTED ANALYTICAL PROCEDURE DEVELOPMENT APPROACH. 2022 , 59, 57-65	0
18	Three courses of treatment increase the efficacy of neoadjuvant immunochemotherapy in patients with local advanced ESCC without increasing TRAEs compared with two courses of treatment.	0
17	Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. 2022 , 14, 5820	0
16	Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as First Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. 2022 ,	0
15	Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients.	0
14	Expanding the toolbox of metabolically stable lipid prodrug strategies. 13,	0
13	Perspectives on the nanocarriers with miRNAs for targeting melanoma stemness through epigenetic regulation.	0
12	Cytidine deaminases catalyze the conversion of N (S , O) 4 -substituted pyrimidine nucleosides. 2023 , 9,	0
11	METTL14-dependent maturation of pri-miR-17 regulates mitochondrial homeostasis and induces chemoresistance in colorectal cancer. 2023 , 14,	0
10	Discovery of 5?-Substituted 5-Fluoro-2?-deoxyuridine Monophosphate Analogs: A Novel Class of Thymidylate Synthase Inhibitors.	0

- 9 An HP-TLC densitometric method and fingerprinting for estimating capecitabine and thymoquinone simultaneously and its application in nanoscience using BoxBehnken design. **2022**, 45, 217-225
- 8 Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report.
- 7 Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. **2023**,
- 6 Pigmentaci3n focal acral inducida por capecitabina. **2023**,
- 5 Are more courses of immunochemotherapy beneficial for the short-term outcome of locally advanced esophageal squamous cell carcinoma?.
- 4 New Treatment Options in Metastatic Pancreatic Cancer. **2023**, 15, 2327
- 3 Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies. 11,
- 2 Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.
- 1 Chemotherapy. **2023**, 7-159